Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Emerson Electric Co. (EMR) vs Medpace Holdings Inc (MEDP) Price & Performance

Emerson Electric Co.Trade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Emerson Electric Co. vs Medpace Holdings Inc — how do they compare? Emerson Electric Co. trades at $163.8 (market cap $91.69B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Emerson Electric Co. is far larger — about 5.4× Medpace Holdings Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

EMRMEDP
Market Cap
$91.69B$16.90B
Sector
IndustrialsTechnology
52-Week High
$164.38$620.59
52-Week Low
$123.30$393.42
Enterprise Value
$102.77B$16.52B
Dividend Yield
1.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Emerson Electric Co.

Emerson Electric (EMR) trades at $164.02, up 3.36% with strong technical momentum and bullish analyst sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding expectations. Recent acquisition of Glue Inc. enhances AI capabilities in test & measurement, supporting the raised 2026 outlook. Valuation metrics show P/E of 35.97 and P/S of 4.97, while profitability remains solid with 13.83% net margin.

EMR presents a favorable risk-reward profile with consensus price target of $171.33 offering 4.5% upside potential. Strong organic growth and AI integration drive optimism, though elevated valuation and overbought technical indicators warrant caution. The stock's proximity to 52-week highs suggests near-term consolidation may precede further gains based on execution of growth initiatives.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Emerson Electric Co.

Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.

Read more on EMR

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP